Skip to main content

Table 2 Clinical details of patients experiencing disease reactivation

From: Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine

 

Patient #1

Patient #2

Patient #3

Sex

F

F

F

Age

47

60

58

RMD diagnosis

PsA

RA

PsA

Ongoing treatment

None

MTX

TNFi

Type of flare

III PIP arthritis

Inflammatory polyarthralgia

Inflammatory back and neck pain

Days from II dose of vaccine

18

10

3

Action taken

None

Glucocorticoids

(4 days)

NSAID

(once)

Outcome

Resolved in 10 days

Resolved in 10 days

Resolved in 3 days

  1. PsA psoriatic arthritis, RA rheumatoid arthritis, MTX methotrexate, TNFi tumor necrosis factor inhibitor, PIP proximal interphalagneal, NSAIDs non-steroidal anti-inflammatory drug